MIAMI, December 28, 2012 /PRNewswire/ --

EmergingGrowth.com, a leading digital financial media company, Reports on RVPlus, Inc., Oil and Gas and Patents infringement in Pharmaceuticals.  

Feature your company on EmergingGrowth.com. Visit EmergingGrowth.com to find out how.  

RV Plus (OTCBB: RVPL) just announced that it has generated a total amount of $14,610,576 in accounts receivable as of today for 2012 year from long-term contracts with foreign governments to supply goods and services that support carbon-emissions reduction, energy efficiency, in addition to supporting climate change, environment, forestry, social affairs, and agriculture.

In the past six months, the company has made entry into three definitive material agreements with foreign government parties for goods and services, holding a total value of $1,900,500,000 (USD), which are associated to Civil Society Programs, collectively organized by United Nations affiliates and Parties in Latin America, West Indies, and Africa.

Cary Lee Peterson has told press that he will be publishing a year-end letter to shareholders on January 1, 2013 to recap on 2012 year for the Company and provide details of plans for ECCO2 Tech and partners in 2013.   If RVPL can materialize these contracts in the near term, we could see a dramatic move in the company's valuation and share price.  Please visit the Company's website for a deeper understanding on the process.  http://www.ecco2tech.com/investors.html

Tamm Oil and Gas Corporation (OTCBB: TAMO) recently entered into an agreement with private company CEC North Star Energy Ltd to do work pertaining to their recently purchased additional third party trade seismic which after reprocessing and analysis continues to support the existence of the Bluesky channel of the Norh Star Lands.  Based on this seismic, 4 well locations were surveyed recently and the licensing process will be initiated in the next few weeks with an expected completion prior to break up. 

Globalstar, Inc. (OTCBB: GSAT) recently announced that it received a delisting notice from NASDAQ do to the fact that it's share price has fallen below $1.00 per share in excess of the time period permitted by NASDAQ rules.  The company after a recent appeal to NASDAQ requested a further extension and was denied.  

The six time patent infringement in pharmaceuticals case plaintiff Depomed (NASDAQ: DEPO) is making progress in battles.  Watson Pharmaceuticals (NYSE: WPI) withdrew its application for the competing drug generic Gralise, and the suit against Impax Laboratories (NASDAQ: IPXL) was dismissed after the withdrawal of their application.  The road is getting clearer as the competition is fading.  Look for Depomed to react.  

About EmergingGrowth.com

By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.

Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack.  Sign up today to see what EmergingGrowth.com has to offer.

NEW:  Feature your company on EmergingGrowth.com.  Find out how by filling out our form at http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth

Join our Linked in Group

Like us on Facebook

Disclosure

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. From time to time, EmergingGrowth.com receives compensation by the companies profiled in its emails, press releases or on its website. If any compensation is received it appears fully detailed in a "special disclosure" on our website as well as on any pages or emails where that company is located.  Please check the "Special Disclosure" link (http://www.emerginggrowth.com/special-disclosure) and consult an investment professional before investing in anything viewed within.  In addition, Please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website. Always remember that investing in securities such as the ones listed within are for high-risk tolerant individuals only and not the general public. Whether you are an experienced investor or not, you should always consult with a stockbroker, financial advisor, or similar before purchasing or selling any securities viewed on any emails sent from EmergingGrowth.com or its website.

SOURCE EmergingGrowth.com